<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04312048</url>
  </required_header>
  <id_info>
    <org_study_id>isosorbide mononitrate IUD</org_study_id>
    <nct_id>NCT04312048</nct_id>
  </id_info>
  <brief_title>the Effect of Isosorbide Mononitrate in Reducing Pain During Cooper Intrauterine Device Insertion</brief_title>
  <official_title>the Effect of Vaginal Isosorbide Mononitrate Administration in Reducing Pain During Cooper Intrauterine Device Insertion in Nulliparous Women : a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the aim of the study is to evaluate the efficacy of isosorbide mononitrate vaginal
      administration in reducing pain during copper IUD insertion in nulliparous women
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 25, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain during IUD insertion</measure>
    <time_frame>5 minutes</time_frame>
    <description>intensity of patient-perceived pain at time of IUD insertion, using a visual analog scale. The VAS scale is graded from 0 to 10 on a 10 cm horizontal straight line, where 'zero' corresponds to no pain at all, and '10' to the worst possible pain imaginable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of IUD insertion</measure>
    <time_frame>5 minutes</time_frame>
    <description>duration of IUD insertion from speculum in to speculum out</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>IUD Insertion Pain</condition>
  <arm_group>
    <arm_group_label>Isosorbide Mononitrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to copper IUD insertion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one tablet of placebo vaginally 3 hours prior to copper IUD insertion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosorbide mononitrate</intervention_name>
    <description>one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to copper IUD insertion</description>
    <arm_group_label>Isosorbide Mononitrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>one tablet of placebo vaginally 3 hours prior to copper IUD insertion</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  nulliparous women requesting copper IUD device insertion

        Exclusion Criteria:

          -  parous women, contraindications to IUD insertion, allergy or contraindication to
             isosorbide mononitrate, uterine anomaly
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AHMED SAMY</last_name>
    <phone>+201100681167</phone>
    <email>ahmedsamy8233@gmail.com</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 14, 2020</study_first_submitted>
  <study_first_submitted_qc>March 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>March 14, 2020</last_update_submitted>
  <last_update_submitted_qc>March 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Samy aly ashour</investigator_full_name>
    <investigator_title>assistant professor obstetrics and gynecology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

